A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer

Hiromi Kataoka,Yoshinori Mori,Takaya Shimura,Hirotada Nishie,Makoto Natsume,Hisato Mochizuki,Yoshikazu Hirata,Satoshi Sobue,Takashi Mizushima,Hitoshi Sano,Yusuke Mizuno,Makoto Nakamura,Atsuyuki Hirano,Kenji Tsuchida,Kazunori Adachi,Kyoji Seno,Mika Kitagawa,Takashi Kawai,Takashi Joh

A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer

2016

Hiromi Kataoka
Yoshinori Mori
Takaya Shimura
Hirotada Nishie
Makoto Natsume
Hisato Mochizuki
Yoshikazu Hirata
Satoshi Sobue
Takashi Mizushima
Hitoshi Sano
Yusuke Mizuno
Makoto Nakamura
Atsuyuki Hirano
Kenji Tsuchida
Kazunori Adachi
Kyoji Seno
Mika Kitagawa
Takashi Kawai
Takashi Joh

Background We evaluated the efficacy and safety of 5-weekly S-1 and cisplatin combined with trastuzumab, a monoclonal antibody against human epidermal growth factor receptor type 2 (HER2) for HER2-positive advanced gastric cancer (AGC).

Keywords:

Prospective cohort study
Human epidermal growth factor
Response Evaluation Criteria in Solid Tumors
Trastuzumab
Cancer
Cisplatin
Tegafur
Monoclonal antibody
Oncology
Internal medicine
Medicine
human epidermal growth factor receptor
advanced gastric cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations